STEP trial programme: difference between revisions
Diff·revision 4 → 5·20:18, 6 Aug 2024
Difference between revision 4 and revision 5 of STEP trial programme. 3 lines changed; the page grew by 516 bytes.
| Revision 4 — 19:17, 23 Jul 2024 SecretagogueSol (talk) serial comma per PP:MOS 2,343 bytes ±0 | Revision 5 — 20:18, 6 Aug 2024 Chromatokid (talk) state that the trial has reported but is not yet peer-reviewed 2,859 bytes +516 | ||
|---|---|---|---|
| 22 | STEP 2 illustrates a consistent finding in this field: weight response is attenuated in people with type 2 diabetes, for reasons that are not established. STEP 3 shows that intensive behavioural support raises both arms rather than only the placebo arm.{{r|davies2021}} | 22 | STEP 2 illustrates a consistent finding in this field: weight response is attenuated in people with type 2 diabetes, for reasons that are not established. STEP 3 shows that intensive behavioural support raises both arms rather than only the placebo arm.{{r|davies2021}} |
| 23 | 23 | ||
| + | 24 | STEP 4 is the informative one for discontinuation. Participants who reached the maintenance dose during a run-in were randomised either to continue or to switch to placebo; the switched group regained weight steadily thereafter. See [[Weight regain after discontinuation]].{{r|rubino2021}} | |
| + | 25 | ||
| 24 | == References == | 26 | == References == |
| 25 | {{reflist}} | 27 | {{reflist}} |
| 26 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> | 28 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> |
| 27 | <ref name="davies2021">Davies M, Færch L, Jeppesen OK, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." ''The Lancet'' 397(10278):971–984 (2021). PMID 33667417.</ref> | 29 | <ref name="davies2021">Davies M, Færch L, Jeppesen OK, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." ''The Lancet'' 397(10278):971–984 (2021). PMID 33667417.</ref> |
| + | 30 | <ref name="rubino2021">Rubino D, Abrahamsson N, Davies M, et al. "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4)." ''JAMA'' 325(14):1414–1425 (2021). PMID 33755728.</ref> | |
| 28 | 31 | ||
| 29 | {{DEFAULTSORT:STEP trial programme}} | 32 | {{DEFAULTSORT:STEP trial programme}} |